A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
This study is testing a new medication called MRTX1719 to see how well it works against advanced solid tumors that have a specific genetic change called an MTAP deletion. By focusing on this specific gene, researchers hope to find a more targeted way to stop cancer cells from growing.
This trial is for adults aged 18 and older with solid tumors that cannot be removed by surgery or have spread to other parts of the body. Participants must have a confirmed MTAP gene deletion and be able to undergo a biopsy, which involves taking a small sample of tumor tissue.
If you join, you will receive the experimental drug MRTX1719 and have regular check-ups to monitor your health and how the cancer responds. You will also need to provide tumor samples via biopsies at specific times throughout the study so researchers can see how the treatment is affecting the tumor.
The study is currently recruiting patients at medical centers in Phoenix, Arizona; Lone Tree, Colorado; and Jacksonville, Florida. As this is a clinical trial, the locations may expand, so it is best to check with your doctor if you are interested.
- 1The study tests an experimental drug specifically for cancers with an MTAP gene deletion.
- 2Participants must be able to have tissue samples collected from their tumor.
- 3This is a Phase 1 study, meaning the primary focus is on safety and finding the right dose.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.